Physician profile
Gregory Alvarez
NPI 1861496754
$11,981.08
in general payments reported to CMS, 2019-2025
22 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $32.70 · 2021: $163 · 2022: $3,846 · 2023: $3,908 · 2024: $3,196 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $6,493 · Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $6,492.72 |
| Food and Beverage | $1,331.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fuse Medical, INC. | $10,027.08 | 2022-2025 | Orbitum Staple System |
| Treace Medical Concepts, INC. | $1,055.88 | 2022-2025 | |
| Nevro Corp. | $194.73 | 2022-2024 | Senza |
| Medtronic, INC. | $166.13 | 2022-2024 | Closurefast, Venaseal |
| Polarityte, INC. | $84.79 | 2021 | |
| Trilliant Surgical LLC. | $77.59 | 2019 | |
| Horizon Therapeutics Plc | $47.13 | 2019-2022 | |
| Bioventus LLC | $44.52 | 2022-2024 | Exogen Ultrasound Bone Healing System |
| Stimwave Technologies Incorporated | $35.31 | 2021 | |
| Organogenesis INC. | $31.92 | 2024 | |
| Hikma Pharmaceuticals USA | $31.49 | 2021 | |
| Stryker Corporation | $31.18 | 2025 | Actishield |
| Grt US Holding, INC. | $25.21 | 2022 | |
| Abbott Laboratories | $21.18 | 2022 | |
| Solventum Corporation | $18.72 | 2025 | Prevena |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $18.23 | 2020 | |
| Reprise Biomedical, INC. | $15.44 | 2022 | |
| Kerecis Limited | $14.05 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Zimmer Biomet Holdings, INC. | $11.92 | 2019 | |
| Nabriva Therapeutics, Plc | $11.56 | 2021 | |
| Merck Sharp & Dohme LLC | $11.16 | 2019 | |
| Dynasplint Systems INC. | $5.86 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.